Related references
Note: Only part of the references are listed.The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists
Sayuri N. Friedland et al.
AMERICAN JOURNAL OF MEDICINE (2012)
Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study
Xuanqi An et al.
CARDIOVASCULAR DIABETOLOGY (2012)
High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)
Hiroyuki Daida et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2012)
The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
Peter P. Toth et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
Tamio Teramoto et al.
CARDIOVASCULAR DIABETOLOGY (2012)
The Controversies of Statin Therapy Weighing the Evidence
J. Wouter Jukema et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
Alexander Tenenbaum et al.
PLOS ONE (2012)
Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
Sandra N. Verhagen et al.
CARDIOVASCULAR DIABETOLOGY (2011)
The metabolic syndrome ... is dead: These reports are an exaggeration
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence
Michel P. Hermans et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome
Barbara C. Hansen et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Pharmacological and non-pharmacological interventions to influence adipose tissue function
Jan Westerink et al.
CARDIOVASCULAR DIABETOLOGY (2011)
Optimal pharmacotherapy to combat the atherogenic lipid triad
M. John Chapman et al.
CURRENT OPINION IN CARDIOLOGY (2011)
Statins and the risk of new-onset diabetes: a review of recent evidence
David Preiss et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
Robert Krysiak et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin Results From 3 Large Randomized Clinical Trials
David D. Waters et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
Michel P. Hermans et al.
CARDIOVASCULAR DIABETOLOGY (2010)
If it ain't broke, don't fix it: a commentary on the positive-negative results of the ACCORD Lipid study
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects
Manoj Mathew et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Comparative Study of Bezafibrate and Pravastatin in Patients With Coronary Artery Disease and High Levels of Remnant Lipoprotein
Keita Sano et al.
CIRCULATION JOURNAL (2010)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun et al.
LANCET (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
Peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) acts as regulator of metabolism linked to multiple cellular functions
Kay-Dietrich Wagner et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Swapnil N. Rajpathak et al.
DIABETES CARE (2009)
Antidiabetic Action of Bezafibrate in a Large Observational Database
James H. Flory et al.
DIABETES CARE (2009)
The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
Jean-Charles Fruchart et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia
Makoto Ayaori et al.
ATHEROSCLEROSIS (2008)
Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia
Ilan Goldenberg et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Rosuvastatin in older patients with systolic heart failure
John Kjekshus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes
Helena Tenenbaum et al.
ATHEROSCLEROSIS (2007)
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level
Aki Hiuge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
Jonathan D. Brown et al.
CIRCULATION (2007)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
A Tenenbaum et al.
EUROPEAN HEART JOURNAL (2005)
Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia - a nuclear magnetic resonance study
K Ikewaki et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
PPARs: therapeutic targets for metabolic disease
JP Berger et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy
C Hanefeld et al.
CARDIOVASCULAR DRUGS AND THERAPY (2005)
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Alexander Tenenbaum et al.
CARDIOVASCULAR DIABETOLOGY (2005)
PPARs and the complex journey to obesity
RM Evans et al.
NATURE MEDICINE (2004)
Regulation of muscle fiber type and running endurance by PPARδ
YX Wang et al.
PLOS BIOLOGY (2004)
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
A Tenenbaum et al.
CIRCULATION (2004)
The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells
U Dressel et al.
MOLECULAR ENDOCRINOLOGY (2003)
Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin plus fibrate (Bezafibrate, fenofibrate, or gemfibrozil)
M Farnier et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death
W El-Assaad et al.
ENDOCRINOLOGY (2003)
Bezafibrate is a dual ligand for PPARα and PPARβ:: studies using null mice
JM Peters et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2003)
Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity
YX Wang et al.
CELL (2003)
Bezafibrate-induced improvement in glucose uptake and endothelial function in protease inhibitor-associated insulin resistance
T Nyström et al.
JOURNAL OF INTERNAL MEDICINE (2002)
Bezafibrate in men with lower extremity arterial disease: randomised controlled trial
T Meade et al.
BRITISH MEDICAL JOURNAL (2002)
Effects of fibrates on metabolism of statins in human hepatocytes
T Prueksaritanont et al.
DRUG METABOLISM AND DISPOSITION (2002)
Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: Reversal with bezafibrate therapy in a randomized controlled trial
IJ Jonkers et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate
JF Meco et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2001)
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate
C Kyrklund et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine
H Poirier et al.
BIOCHEMICAL JOURNAL (2001)
Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients
A Taniguchi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors - The prospective pravastatin pooling project
FM Sacks et al.
CIRCULATION (2000)
Interactions between insulin resistance and insulin secretion in the development of glucose intolerance
MK Cavaghan et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
JT Backman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)
P Pauciullo et al.
ATHEROSCLEROSIS (2000)
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety
D Gavish et al.
JOURNAL OF INTERNAL MEDICINE (2000)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Bezafibrate reduces blood glucose in type 2 diabetes mellitus
S Ogawa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
Share Paper
